Product Description
Teriparatide is a recombinant human parathyroid hormone analog comprising the first 34 amino acids (the biologically active N-terminal region) of the endogenous 84-amino acid hormone. Known commercially by trade names like Forteo or Forsteo, it functions as a highly potent bone anabolic agent. Unlike alternative medications that merely slow bone loss, Teriparatide actively stimulates new bone formation, making it a critical therapeutic pipeline for treating severe metabolic bone disorders.
Product benefits
True Anabolic Bone Formation: Unlike traditional anti-resorptive therapies that merely slow down bone loss, Teriparatide actively builds new bone. By intermittently activating osteoblasts (bone-forming cells), it systematically increases bone mass, thickness, and overall skeletal volume.
Proven Fracture Risk Reduction: Extensive clinical data confirms that Teriparatide rapidly reinforces skeletal microarchitecture. Regular administration significantly reduces the incidence of both vertebral (spine) and non-vertebral fractures in high-risk patients.
Rapid Increases in Bone Mineral Density (BMD): Teriparatide delivers a powerful anabolic response, driving substantial and measurable increases in bone mineral density. It is highly effective at targeted structural repair in the lumbar spine and femoral neck regions.
Reversal of Steroid-Induced Bone Loss: It is a validated treatment for glucocorticoid-induced osteoporosis. Teriparatide directly counters the bone-wasting side effects of long-term systemic corticosteroid use (such as prednisone) by reviving suppressed bone-building pathways.
Clinical Success in Severe, Resistant Cases: Teriparatide provides a critical therapeutic path for patients with severe metabolic bone disease who have failed or cannot tolerate standard treatments (such as bisphosphonates), offering an advanced solution for complex bone maintenance.